@entity302 in @entity463 ( @entity463 ) @entity1 is common. @entity1503 is a potential side effect of @entity734 ( @entity734 ) and a frequent limiting-dose effect of @entity2903 ( @entity2904 ). The aim of the study was to investigate the impact of @entity734 on @entity882 in @entity463 @entity1 treated with radiotherapy and @entity2904 . A cohort of 101 newly diagnosed @entity463 @entity1 treated with radiotherapy and @entity2904 was reviewed. Clinical data, presence of @entity410 , @entity734 use, platelet count, and accumulated @entity2904 dose were analyzed at each cycle. @entity882 was operationalized as a continuous platelet count and a dichotomic variable (cut-off <100.000/mm(3)). This cut-off represents the threshold beyond which @entity2904 treatment is modified. A linear and a probit pooled cross-sectional regression analysis were used to study the impact of age, gender, @entity734 , and accumulated @entity2904 on @entity882 . Impact of @entity734 on survival was also analyzed. Thirty-five @entity1 (35%) presented @entity410 at onset and 18 (27%) during follow-up. Seven (13%) needed two or more @entity734 for @entity410 control. Grade 3-4 @entity882 was found in 8%. @entity1423 was related to accumulated @entity2904 (p  <  0.001), age (p  <  0.001), and @entity1092 (p  =  0.004). Platelet count <100.000/mm(3) was only associated with accumulated @entity2904 (p  =  0.001). Recursive Partitioning Analysis prognostic class was the only variable with significant impact on survival. @entity1092 and age had an independent negative effect on total platelet count, although neither had an effect on critical @entity882 (<100.000/mm(3)). Therefore, the systematic withhold of valproate in @entity463 @entity1 might not be justified. Nevertheless, this negative effect may be taken into account especially in elderly @entity1 .

Impact of @entity734 on @entity882 in @entity463 XXXX treated with standard chemoradiotherapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures'] @entity882 :: ('MESH:D013921', 'Disease') :: ['Thrombocytopenia', 'thrombocytopenia'] @entity1423 :: ('MESH:D001791', 'Disease') :: ['Decrease in platelet count'] @entity2904 :: ('CHEBI:72564', 'Chemical') :: ['TMZ'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['valproate', 'Valproate'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['Hematological toxicity'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma multiforme', 'GBM'] @entity302 :: ('MESH:D004827', 'Disease') :: ['Epilepsy'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity734 :: ('MESH:D019966', 'Disease') :: ['AEDs', 'antiepileptic drugs']
@entity1 :: (9606,Species) :: ['patients']
